Skip to main content

Hyperphagia in Prader-Willi Syndrome

1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Acadia Pharmaceuticals
1 program
1
carbetocinPhase 32 trials
Active Trials
NCT06420297Terminated168Est. Dec 2025
NCT06173531Completed175Est. Aug 2025
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
FE 992097PHASE_21 trial
Active Trials
NCT01968187Completed38Est. Jul 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Acadia Pharmaceuticalscarbetocin
Acadia Pharmaceuticalscarbetocin
Ferring PharmaceuticalsFE 992097

Clinical Trials (3)

Total enrollment: 381 patients across 3 trials

OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Start: Mar 2024Est. completion: Dec 2025168 patients
Phase 3Terminated

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Start: Nov 2023Est. completion: Aug 2025175 patients
Phase 3Completed

Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome

Start: Jan 2014Est. completion: Jul 201438 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.